{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'Note: for confirmed asymptomatic cases, the period of contact is measured as the 2 days', 'before through the 14 days after the date on which the sample was taken which led to', 'confirmation.', '163']['2017N331008_06', 'CONFIDENTIAL', '208090', '11.15.', 'Appendix 15: Protocol Amendment History', 'The Protocol Amendment Summary of Changes Table for the current amendment is', 'located directly before the Table of Contents (TOC).', 'Amendment 01, 26-MAR-2018', 'Overall Rationale for the Amendment: A global amendment applicable to all', 'participating countries to clarify entry criteria, correct errors and improve consistency.', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 1.2: Schema', 'Changed DTG + 3TC to DTG/3TC FDC', 'To improve', 'Section 8.1.3: Exploratory', 'consistency', 'Efficacy Endpoints', 'Section 9.4.1: Efficacy', 'Analyses', 'X was removed at Week 4 and Week 52 for PK', 'Section 1.3: Schedule of', 'To correct an error', 'Activities (SoA)', 'sampling', 'in the original', 'protocol', 'Section 2.3.1: Risk', 'Updated DTG: Drug induced liver injury (DILI) and', 'To provide updated', 'Assessment', 'other clinically significant liver chemistry elevations', 'language to further', \"to add: 'A review of postmarketing data found that\", 'inform risk', 'the number of cases reporting particularly severe', 'assessment', 'liver dysfunction was found to be very low in the', 'context of exposure to DTG and DTG/ABC/3TC.', 'The reported cases of severe liver dysfunction', '(including acute hepatic failure) are complex with', 'potential confounding factors but in a very small', 'number of cases, drug-induced liver injury is likely', 'and the role of DTG containing regimens cannot', 'be ruled out particularly in those involving DTG', 'with ABC/3TC or DTG/ABC/3TC.', 'Section 4.1: Overall Design,', 'Updated Phase IIIb to Phase III', 'To clarify study', 'Protocol Title, Short Title', 'Phase', 'Section 5.1: Inclusion Criteria', \"Inclusion criterion 5 was updated to add 'or from\", 'To clarify the study', 'tenofovir disoproxil fumarate (TDF) to tenofovir', 'population intended', \"alafenamide (TAF)' to read 'A switch from a PI\", 'to be enrolled; to', 'boosted with RTV to the same PI boosted with', 'align inclusion', 'cobicistat is allowed (and vice versa). A switch', 'criterion 6 with the', 'from lamivudine (3TC) to emtricitabine (FTC) or', '28 day Screening', 'from tenofovir disoproxil fumarate (TDF) to', 'period', 'tenofovir alafenamide (TAF) is also allowed (and', 'vice versa).', \"Inclusion criterion 6 updated '30 days' to '28 days'\", \"to read 'A WOCBP who agrees to follow the\", '164']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'contraceptive guidance in Section 11.3.2 during the', 'treatment period from 28 days prior to the first dose', 'of study medication and until the last dose of study', 'medication and completion of the follow-up visit.', 'The investigator should evaluate the effectiveness', 'of the contraceptive method in relationship to the', \"first dose of study intervention.'\", 'Section 5.2: Exclusion Criteria', 'Exclusion Criterion 5 was updated to add', 'To clarify the study', \"'Participants with a documented history of chronic\", 'HBV and current undetectable HBV DNA while on', 'population intended', 'to be enrolled', \"a TAF/TDF regimen are excluded.'\", \"Exclusion Criterion 20 was updated to remove 'with\", \"the exception of Grade 4 lipid abnormalities' to\", 'read \"Any verified Grade 4 laboratory abnormality.', 'A single repeat test is allowed during the Screening', \"period to verify a result.'\", 'Amendment 02, 14-NOV-2018', 'Overall Rationale for the Amendment: A global amendment applicable to all', 'participating countries to update the study design including length of study, updates to the', 'eligibility criteria and removing the option to remain on the study if the participant', 'becomes pregnant. Additional changes were made to manage and mitigate risks', 'following identification of a potential safety issue related to neural tube defects in infants', 'born to women with exposure to dolutegravir at the time of conception. A sub-study was', 'added to collect data on participants who withdraw for meeting CVW or PVW criteria.', '165']\n\n###\n\n", "completion": "END"}